Sökning: id:"swepub:oai:research.chalmers.se:26dc76ab-c572-43e1-abb9-00c5ffc73d18" >
Evaluation of ATOX1...
Evaluation of ATOX1 as a potential predictive biomarker for tetrathiomolybdate treatment of breast cancer patients with high risk of recurrence
-
- Blockhuys, Stephanie, 1983 (författare)
- Chalmers tekniska högskola,Chalmers University of Technology,Chalmers Univ Technol, Sweden
-
- Hildesjö, Camilla (författare)
- Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Regionalt cancercentrum
-
- Olsson, Hans (författare)
- Linköpings universitet,Avdelningen för neurobiologi,Medicinska fakulteten,Region Östergötland, Klinisk patologi
-
visa fler...
-
- Vahdat, Linda (författare)
- Memorial Sloan-Kettering Cancer Center,Mem Sloan Kettering Canc Ctr, NY 10065 USA
-
- Wittung Stafshede, Pernilla, 1968 (författare)
- Chalmers tekniska högskola,Chalmers University of Technology,Chalmers Univ Technol, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2021-12-12
- 2021
- Engelska.
-
Ingår i: Biomedicines. - : MDPI AG. - 2227-9059. ; 9:12
- Relaterad länk:
-
https://research.cha... (primary) (free)
-
visa fler...
-
https://www.mdpi.com...
-
https://liu.diva-por... (primary) (Raw object)
-
https://doi.org/10.3...
-
https://research.cha...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Copper plays a key role in cancer metastasis, which is the most common cause of cancer death. Copper depletion treatment with tetrathiomolybdate (TM) improved disease-free survival in breast cancer patients with high risk of recurrence in a phase II clinical trial. Because the copper metallochaperone ATOX1 was recently reported to drive breast cancer cell migration and breast cancer migration is a critical factor in metastasis, we tested if ATOX1 expression levels in primary tumor tissue could predict the TM treatment outcome of breast cancer patients at high risk of recurrence. We performed ATOX1 immunohistochemical staining of breast tumor material (before TM treatment) of 47 patients enrolled in the phase II TM clinical trial and evaluated ATOX1 expression levels in relation with patient outcome after TM treatment. Our results show that higher ATOX1 levels in the tumor cell cytoplasm correlate with a trend towards better event-free survival after TM treatment for triple-negative breast cancer patients and patients at stage III of disease. In conclusion, ATOX1 may be a potential predictive biomarker for TM treatment of breast cancer patients at high risk of recurrence and should be tested in a larger cohort of patients.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- ATOX1
- Breast cancer
- Tetrathiomolybdate
- Clinical trial
- Copper depletion
- Biomarker
- Event-free survival
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas